Gert Van Assche

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. pmc Treatment of severe steroid refractory ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
    World J Gastroenterol 14:5508-11. 2008
  2. ncbi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
  3. doi request reprint The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety
    Gert Van Assche
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:1594-602; quiz 1593, 1603. 2011
  4. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
  5. doi request reprint Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:748-61. 2011
  6. pmc Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease
    Christine Breynaert
    Translational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    PLoS ONE 8:e68876. 2013
  7. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
  8. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
  9. ncbi request reprint Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Joris Arts
    Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:73-8. 2004
  10. doi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010

Detail Information

Publications89

  1. pmc Treatment of severe steroid refractory ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
    World J Gastroenterol 14:5508-11. 2008
    ..Therefore, patients not responding to these agents within 5-7 d should be considered for colectomy and responders should be closely monitored for infections...
  2. ncbi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
    ..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
  3. doi request reprint The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety
    Gert Van Assche
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:1594-602; quiz 1593, 1603. 2011
    ..This may enhance both therapeutic efficacy and the risk of infection or malignancy, so the balance of risk and benefit must be judged for individual patients...
  4. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
    ..Unequivocal histologic markers predicting recurrence have not been identified. We assessed the predictive value of neural lesions for early endoscopic CD recurrence and long-term reintervention risk...
  5. doi request reprint Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:748-61. 2011
    ..This migration is regulated by cell adhesion molecules (CAMs), and selective antimigration therapies have been developed. This study investigated the effect of infliximab therapy on the mucosal gene expression of CAMs in IBD...
  6. pmc Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease
    Christine Breynaert
    Translational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    PLoS ONE 8:e68876. 2013
    ..The aim of this study was to investigate changes in connective tissue in a chronic murine model resulting from repeated cycles of dextran sodium sulphate (DSS) ingestion, to mimic the relapsing nature of the human disease...
  7. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
    ..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
  8. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  9. ncbi request reprint Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Joris Arts
    Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:73-8. 2004
    ..It remains unclear if this treatment affects the course of the disease in the long run. We investigated the long-term efficacy and safety in 86 patients with ulcerative colitis treated with i.v. CSA at our center...
  10. doi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010
    ..In case reports, thiopurine analogs and infliximab (IFX) have been proposed as effective therapy in this setting. We analyzed the long-term efficacy of IFX in Belgian patients with refractory pouch complications...
  11. doi request reprint Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:2090-8. 2010
    ..However, a subset of patients shows incomplete or no response to this agent. In this study we investigated whether we could identify a mucosal gene panel to predict (non)response to IFX in CD...
  12. doi request reprint Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 15:1295-301. 2009
    ..Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated...
  13. ncbi request reprint Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls
    Talat Bessissow
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium Department of Gastroenterology, Royal Victoria Hospital, McGill University Health Center, Montreal, Canada Electronic address
    J Crohns Colitis 7:e580-7. 2013
    ..Pain and nausea are often reported during bowel cleansing (BC) for ileocolonoscopy (IC). We aimed to explore putative mechanisms associated with impaired tolerance to BC...
  14. doi request reprint Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis
    Bart Lemmens
    Translational Cell and Tissue Research, Department of Imaging and Pathology, University Hospital KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 19:1194-201. 2013
    ..It is still unknown how well they correlate and whether scoring both endoscopy and histology better reflects the true disease activity than each of the methods separately...
  15. ncbi request reprint Protein-losing enteropathy in Crohn's disease
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Acta Gastroenterol Belg 69:384-9. 2006
    ..Histology showed severe mesenteric granulomatosis, dilated lymph vessels and granulomatous vasculitis. After the resection our patient improved without further albumin infusions and the oedema resolved...
  16. doi request reprint Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing
    Talat Bessissow
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 107:1684-92. 2012
    ..We aimed to investigate the predictive role of serologic and histologic markers on disease relapse in UC patients with endoscopically inactive disease...
  17. doi request reprint Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
    Konstantinos Karmiris
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 137:1628-40. 2009
    ....
  18. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
    ..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
  19. doi request reprint Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 25:323-8. 2009
    ..To focus on the emerging clinical evidence for the use of traditional immunosuppressives and biologicals in the treatment of inflammatory bowel disease...
  20. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003
    ..We evaluated the clinical significance of these antibodies in patients with Crohn's disease...
  21. doi request reprint Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease
    Mirjam Bueno de Mesquita
    Department of Paediatric Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Eur J Pediatr 168:575-83. 2009
    ..6%, respectively, p<0.0001) and more often had concomitant immune-mediated diseases and a trend for more seroreactivity towards ASCA...
  22. ncbi request reprint Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
    Gert Van Assche
    Department of Gastroenterology, University of Leuven, 49, Herestraat, Leuven 3000, Belgium
    Gastroenterology 125:1025-31. 2003
    ..Our single center, randomized, double-blind, controlled trial aimed to evaluate the additional clinical benefit of 4 mg/kg over 2 mg/kg IV cyclosporine in the acute treatment of severe UC...
  23. ncbi request reprint Mucosal healing and anti TNFs in IBD
    Gert Van Assche
    Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium
    Curr Drug Targets 11:227-33. 2010
    ..In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered...
  24. doi request reprint Effects of T cell-induced colonic inflammation on epithelial barrier function
    Peter Suenaert
    Division of Gastroenterology, University Hospital, Leuven, Belgium
    Inflamm Bowel Dis 16:1322-31. 2010
    ....
  25. ncbi request reprint Serum sickness, encephalitis and other complications of anti-cytokine therapy
    Severine Vermeire
    University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:101-12. 2009
    ..We discuss the safety aspects of the biological agents in this chapter and, where available, give ways to prevent and/or treat them...
  26. ncbi request reprint Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease
    Philippe Maerten
    Clinical Immunology, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium
    Clin Immunol 112:239-46. 2004
    ..Taken together, our data suggest that 4-1BB/4-1BBL interactions contribute to the persistence of gut inflammation in CD...
  27. doi request reprint Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease
    Matthias Jürgens
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 9:421-7.e1. 2011
    ..C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab...
  28. doi request reprint Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 17:1846-54. 2011
    ..Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy...
  29. pmc New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gut 56:1394-403. 2007
    ....
  30. pmc Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    PLoS ONE 4:e7984. 2009
    ..We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD...
  31. pmc Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab
    Clémentine Perrier
    Department of Gastroenterology, Translational Research Centre for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium
    Immunology 138:47-56. 2013
    ..Expression is localized in B cells, suggesting that IL-15 regulates B-cell functions during bowel inflammation. No change in release of sIL-15Rα is observed in patients treated with IFX...
  32. doi request reprint Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients
    Marko Brinar
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    J Crohns Colitis 6:43-50. 2012
    ..Genetic variants in autophagy genes IRGM and ATG16L1 have been associated with susceptibility to Crohn's disease. We therefore investigated whether variants in autophagy genes contribute to granuloma formation...
  33. ncbi request reprint Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 14:20-8. 2008
    ..During the course of their disease, about 30% of patients with ulcerative colitis (UC) will undergo proctocolectomy with ileal pouch-anal anastomosis (IPAA). We evaluated the outcome of IPAA in a Belgian referral center...
  34. doi request reprint Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
    Zhe Li
    Laboratory of Experimental Immunology, Catholic University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 16:1299-310. 2010
    ..Therefore, we investigated the effect of infliximab (IFX) therapy on Forkhead box protein3 (Foxp3) T cells in blood and intestinal mucosa from Crohn's disease (CD) and ulcerative colitis (UC)...
  35. doi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...
  36. doi request reprint Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging
    Konstantinos Karmiris
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 9:130-6. 2011
    ..Magnetic resonance imaging (MRI) is used to assess the outcome of infliximab (IFX) therapy in patients with perianal fistulizing Crohn's disease (pfCD). However, few long-term data are available about its efficacy...
  37. doi request reprint Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis
    Clémentine Perrier
    Department of Gastroenterology, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 19:246-53. 2013
    ..The aim of this study was to determine whether neutralization of sTNF exclusively, by the use of a dominant negative mutant of TNF (XENP1595), could reduce the severity of colitis in mice...
  38. ncbi request reprint C-reactive protein as a marker for inflammatory bowel disease
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:661-5. 2004
    ..However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate...
  39. doi request reprint Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study
    Christine Breynaert
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Am J Gastroenterol 106:778-85. 2011
    ..The primary end point was the incidence of infusion reactions in both groups...
  40. ncbi request reprint Long-term outcome after infliximab for refractory ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Crohns Colitis 2:219-25. 2008
    ..We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified...
  41. ncbi request reprint Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis
    David N Moskovitz
    Department of Internal Medicine, University Hospital, Gasthuisberg Herestraat, Leuven, Belgium
    Clin Gastroenterol Hepatol 4:760-5. 2006
    ..Cyclosporine (CSA) has been shown to be effective in steroid-refractory ulcerative colitis (UC) and as an alternative to glucocorticosteroids in patients with severe attacks of UC. Our aim was to investigate the long-term efficacy of CSA...
  42. ncbi request reprint Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 35:743-56. 2006
    ..The advent of newer anti-TNF agents is only postponing the answer...
  43. ncbi request reprint Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model
    Chong Shen
    Laboratory of Experimental Immunology, Campus Gasthuisberg O and N, Herestraat 49, B 3000 Leuven, Belgium
    Clin Immunol 115:250-9. 2005
    ..These data provide support for caspase-dependent apoptosis induction being the mechanism of action of infliximab in vivo...
  44. ncbi request reprint Predictors of early response to infliximab in patients with ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:123-8. 2007
    ..Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response...
  45. ncbi request reprint Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Curr Gastroenterol Rep 11:504-8. 2009
    ..Finally, it remains unclear if and when a biologic agent can be stopped in patients with long-standing remission...
  46. ncbi request reprint Endoscopic therapy of strictures in Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospital, Leuven, Belgium
    Inflamm Bowel Dis 13:356-8; discussion 362-3. 2007
  47. doi request reprint Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospitals, 49 Herestraat, 3000 Leuven, Belgium
    J Crohns Colitis 4:329-33. 2010
    ..We aimed to prospectively assess the safety and tolerance of infliximab infusion in patients with IBD in a specialized unit adhering to strict standard operation procedures including switch to accelerated 1h infusions...
  48. ncbi request reprint Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
    J Crohns Colitis 2:142-51. 2008
    ..We investigated the role of antimicrobial and antiglycan antibodies and polymorphisms in microbial pattern recognition receptor genes...
  49. ncbi request reprint Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study
    Severine Vermeire
    Gastroenterology Department, University Hospital Gasthiuisberg, Leuven, Belgium
    Gastroenterology 125:32-9. 2003
    ..We investigated the occurrence of antinuclear antibodies in 125 consecutive Crohn's disease patients and studied the relationship with symptoms of autoimmunity...
  50. ncbi request reprint Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    N Engl J Med 353:362-8. 2005
    ..There was staining of the brain lesion for polyomavirus. This case report, along with two others, suggests that anti-alpha4-integrin therapy can result in JC virus-induced PML...
  51. ncbi request reprint Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease
    Tibor Hlavaty
    University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:199-204. 2006
    ..Whereas the validity and reproducibility of the IBDQ have been extensively studied, there are limited data on its short-term responsiveness and cutoff values for remission and partial clinical response...
  52. ncbi request reprint Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model
    Chong Shen
    Laboratory of Experimental Immunology, Catholic University, Leuven, Belgium
    Inflamm Bowel Dis 12:22-8. 2006
    ..Besides neutralization, induction of apoptosis of monocytes/macrophages and T cells is thought to be an important mechanism of action of the anti-tumor necrosis factor monoclonal antibody infliximab, at least in Crohn's disease therapy...
  53. ncbi request reprint Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis
    Magali de Bruyn
    Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium and Montefiore Institute, Electrical Engineering and Computer Science, University of Liege, Liege, Belgium
    Inflamm Bowel Dis 20:1198-207. 2014
    ..The current standard for the assessment of mucosal healing after therapy in inflammatory bowel diseases is endoscopy. However, a high need exists for noninvasive, accurate surrogate markers...
  54. doi request reprint Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme
    Marc Ferrante
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    J Crohns Colitis 6:116-31. 2012
    ..Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers...
  55. doi request reprint Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    Geert D'Haens
    Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 18:2218-24. 2012
    ..Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity...
  56. ncbi request reprint Medical treatment of inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 21:443-7. 2005
    ..Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field...
  57. ncbi request reprint Optimizing anti-TNF treatment in inflammatory bowel disease
    Paul Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
    Gastroenterology 126:1593-610. 2004
    ..Other adverse events associated with anti-TNF strategies are demyelinating disease and worsening of congestive heart failure. Malignancy rates in patients treated with anti-TNF strategies do not seem to be increased...
  58. ncbi request reprint Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, Univ Hospital Leuven, 49 Herestraat, B 3000 Leuven, Belgium
    Am J Physiol Gastrointest Liver Physiol 288:G169-74. 2005
    ....
  59. ncbi request reprint Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis
    Chong Shen
    Laboratory of Experimental Immunology, Catholic University of Leuven, Campus Gasthuisberg O and N, Herestraat 49, B 3000 Leuven, Belgium
    Int Immunopharmacol 4:939-51. 2004
    ..The data also provide evidence that glycolipid biosynthesis is involved in the inflammatory cascade in these inflammatory bowel disease (IBD) models...
  60. ncbi request reprint Safety issues with biological therapies for inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 22:370-6. 2006
    ..The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance...
  61. doi request reprint Management of acute severe ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gut 60:130-3. 2011
    ..Whereas prolonged exposure to steroids predisposes to an increased rate of peri-operative complications it is still debated whether cyclosporine or infliximab increase peri-operative morbidity in ulcerative colitis...
  62. ncbi request reprint A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis
    Gert Van Assche
    Department of Gastroenterology, University of Leuven, Belgium
    Am J Gastroenterol 98:369-76. 2003
    ..Because cyclosporine acts by inhibiting interleukin-2 (IL-2) production, we studied the efficacy and safety of humanized anti-IL2 receptor (CD25) antibodies daclizumab for refractory UC in an open label pilot study...
  63. pmc Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Paul Rutgeerts
    University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
    Gut 56:453-5. 2007
    ..We propose that future studies should focus on healing and disease course as primary outcome measures...
  64. ncbi request reprint Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 97:2357-63. 2002
    ..The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab...
  65. ncbi request reprint Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease
    Peter Suenaert
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium
    Am J Gastroenterol 97:2000-4. 2002
    ....
  66. doi request reprint Classification of inflammatory bowel disease: the old and the new
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 28:321-6. 2012
    ..Basic scientists on the other hand prefer classifications that would allow to better understand the pathophysiology of the different manifestations of Crohn's disease and ulcerative colitis...
  67. doi request reprint Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial
    Paul Rutgeerts
    Department of Gastro Enterologie, University Hospital of Gasthuisberg, Leuven, Belgium
    Gastroenterology 142:1102-1111.e2. 2012
    ..We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD)...
  68. doi request reprint Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
    Gert Van Assche
    Division of Gastroenterology and Laboratory for Pharmaceutical Biology, University of Leuven, Leuven, Belgium
    Gut 61:229-34. 2012
    ..A study was undertaken to evaluate prospectively the impact of elective switching of patients with Crohn's disease well controlled with intravenous infliximab to subcutaneous adalimumab in a controlled trial...
  69. doi request reprint Biological therapies for inflammatory bowel diseases
    Paul Rutgeerts
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 136:1182-97. 2009
    ..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
  70. ncbi request reprint Optimizing treatment of inflammatory bowel diseases with biologic agents
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, 49, Herestraat 3000 Leuven, Belgium
    Curr Gastroenterol Rep 10:591-6. 2008
    ....
  71. ncbi request reprint The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:870-8. 2006
    ..Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms...
  72. ncbi request reprint Emerging biological treatments in inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Dig Dis 24:131-6. 2006
    ..As illustrated by unexpected but devastating brain infections with anti-adhesion molecules, clinicians should be aware that the powerful immunomodulatory capacity of biologicals necessitates a rigorous safety follow-up...
  73. doi request reprint (Auto)antibodies in inflammatory bowel diseases
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven Belgium, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 37:429-38, vii. 2008
    ..However, currently, they have no place in the diagnostic work up. Their real promise may lie in their use as surrogate markers of complicated aggressive disease as shown in various retrospective studies, but prospective data are lacking...
  74. pmc Role of genetics in prediction of disease course and response to therapy
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    World J Gastroenterol 16:2609-15. 2010
    ..Nevertheless, the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed...
  75. ncbi request reprint Emerging drugs to treat Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, 49 Herestraat, 3000 Leuven, Belgium
    Expert Opin Emerg Drugs 12:49-59. 2007
    ..Therefore, long-term benefit to risk profiles need to be established for all novel drugs...
  76. ncbi request reprint Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, University Hospital, University of Leuven, Belgium
    Am J Gastroenterol 98:332-9. 2003
    ..The aim of the present study was to assess the behavior of perianal fistulas before and after infliximab treatment...
  77. ncbi request reprint Medical therapy for Crohn's disease strictures
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospital, Herestraat 49, 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:55-60. 2004
    ..Specific medical therapy aimed at preventing or reversing intestinal fibrosis is not yet available, but candidate molecules are emerging from research in the liver and in other organs...
  78. ncbi request reprint Medical management of postoperative recurrence in Crohn's disease
    Gert Van Assche
    Division of Gastroenterology, Department of Internal Medicine, University Hospital Leuven, 49 Herestraat, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 33:347-60, x. 2004
    ..Future well designed collaborative trials with specified end points are needed to optimize clinical practice in the prevention of postoperative Crohn's disease recurrence...
  79. ncbi request reprint CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue
    Klara Gijsbers
    Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    Eur J Immunol 34:1992-2000. 2004
    ..Thus, the chemokine network shows complementarity rather than redundancy...
  80. ncbi request reprint The role of aminosalicylates in the treatment of ulcerative colitis
    Gert Van Assche
    Department of Internal Medicine Gastroenterology, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Acta Gastroenterol Belg 65:196-9. 2002
    ..However, at present there is insufficient evidence to maintain patients on life-long 5-ASA maintenance treatment for this indication...
  81. ncbi request reprint The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Nat Clin Pract Gastroenterol Hepatol 2:580-6. 2005
    ..Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot replace it...
  82. ncbi request reprint Antiadhesion molecule therapy in inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University Hospital Leuven, Belgium
    Inflamm Bowel Dis 8:291-300. 2002
    ..In the near future, these novel biological agents may prove valuable therapeutic tools in the management of refractory IBD...
  83. ncbi request reprint Protein-losing enteropathy in Crohn's disease
    Marc Ferrante
    Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 3:A25. 2005
  84. ncbi request reprint Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
    Marco Daperno
    Gastroenterology Unit, Ospedale Mauriziano Umberto I, Torino, Italy
    Gastrointest Endosc 60:505-12. 2004
    ..The aim of this study was to develop and to prospectively validate a simpler endoscopic score of disease activity, the Simple Endoscopic Score for Crohn's Disease...
  85. doi request reprint Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    Geert D'Haens
    Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
    Lancet 371:660-7. 2008
    ..We aimed to compare the effectiveness of early use of combined immunosuppression with conventional management in patients with active Crohn's disease who had not previously received glucocorticoids, antimetabolites, or infliximab...
  86. ncbi request reprint Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent
    Peter Suenaert
    Division of Gastroenterology, Montreal General Hospital, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Inflamm Bowel Dis 11:667-73. 2005
    ....
  87. ncbi request reprint Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?
    Chong Shen
    Laboratory of Experimental Immunology, Katholike Universiteit Leuven, Belgium
    Inflamm Bowel Dis 13:308-16. 2007
    ..The aim was to investigate the pathogenic role of TNF in hapten-induced colitis models and to study the relationship between apoptosis induction and disease remission...
  88. ncbi request reprint A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis
    Scott Plevy
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA
    Gastroenterology 133:1414-22. 2007
    ....
  89. ncbi request reprint Intramural steroid injection and endoscopic dilation for Crohn's disease
    Gert Van Assche
    Clin Gastroenterol Hepatol 5:1027-8. 2007